Labour MP raises concerns about Asda’s takeover deal
Ashley Dalton believes the proposed deal is ‘debt-laden' and not in the interests of her constituents or the country
By Bill JacobsJun 21, 2023
A LANCASHIRE Labour MP is asking for the competition regulator to investigate Asda’s takeover of the Blackburn-based EG Group’s UK and Ireland business.
Ashley Dalton believes the proposed deal is ‘debt-laden’ and not in the interests of her constituents or the country.
But EG group and Asda, both owned by Blackburn’s billionaire Issa brothers Mohsin and Zuber, dispute her claims.
West Lancashire MP Dalton has written to Kemi Badenoch, secretary of state for business and trade, urging her to ensure the Competition and Markets Authority (CMA) intervenes. Her letter claims that Asda’s debts are already thought to be £4.7 billion and any deal with EG Group could add £7 billion to the total.
Dalton’s letter follows Asda workers GMB trade union writing to Badenoch in April.
She said: “The merger looks set to hugely increase the debt burden on Asda, which will threaten jobs as well as the future of the company.
“As one of the largest private sector employers in the UK, the future sustainability of Asda is important to my constituents that work there. Their livelihoods rely on it. Not only that but many of my constituents do a weekly shop at the store.
“There are serious concerns about the impact for fuel prices with one company having a potential monopoly on access to our petrol pumps.”
An Asda spokesman said: “Asda has acquired EG Group’s UK and Ireland business. It is not merging with EG Group.
“Asda’s net debt post-acquisition will be circa £5bn. “Although Asda have common shareholders in the Issa brothers and TDR Capital – the two companies operate independently. “The £7bn EG Group refinancing will have no impact whatsoever on Asda.
“Asda is the price leader in the fuel market. This position will remain unchanged following the acquisition which means many more motorists will benefit from lower prices at the pumps when the EG UK forecourt sites are converted to Asda petrol stations.
“Asda expects the transaction will be a net jobs creator for both Asda and the EG business.” EG group sources made clear that, as announced in its latest financial results, the company would remain headquartered in nine countries in three continents and that its financial restructuring would reduce the company’s net debt significantly from £7,660million in March to £4,201m after the Asda deal. (Local Democracy Reporting Service)
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.